The Molecular Atlas / Metabolism

By Dissolv Labs · Published October 13, 2026 · Selected sources checked October 13, 2026

Why the numbers are not enough

Fragment names refer to a portion of a parent sequence. A modified fragment can differ from a native segment even when the names look closely related. FDA describes AOD9604 as a synthetic 16-amino-acid peptide related to a portion of human growth hormone and distinguishes its free-base and acetate forms. Read the FDA meeting background.

For a comparison, request the complete sequence, terminal modifications and chemical form for each material. Then compare those details with the tested substance in the paper. A label abbreviation is a starting point for identification, not a substitute for it.

What the early metabolic research investigated

A 2001 study examined AOD9604 in obese mice and mice lacking the beta-3 adrenergic receptor. It investigated lipid-metabolism responses and helped frame mechanistic questions about the fragment. These are animal experiments with defined biological conditions. They are not evidence that a commercially listed research vial produces a desired outcome in humans. Read the original mouse study.

The clinical evidence does not support a simple success story

FDA's 2024 evaluation discusses a larger obesity trial and reports that differences in weight loss relative to placebo did not reach statistical significance at the reported primary and secondary time points. The review also notes limitations in the publicly available study details. That belongs in an evidence summary alongside the earlier mechanistic interest. Read FDA's AOD9604 evidence review.

It would be misleading to select a favorable animal finding and ignore the later clinical uncertainty. It would also be too broad to claim that one trial answers every possible scientific question about a molecule. The accurate conclusion is narrower: the cited research does not justify presenting these catalog materials as established weight-loss treatments.

Three different uses of the word “effect”

A biochemical effect describes a change in a measured process. An experimental outcome describes what happened in a model. A clinical benefit describes an outcome relevant to people in a studied setting. Good explanations retain those distinctions rather than using the same broad promise for all three.

Even when a pathway is plausible, a clinical study must address whether the intervention reaches the relevant site, produces a meaningful result and has acceptable harms in the intended population. Plausibility helps formulate the question; it does not decide the answer.

Before using a paper to describe a listing

Match the substance first. Then match the formulation and experimental context. Finally, check whether the claimed result was actually measured and whether the comparison supported it. If a paper's material cannot be matched confidently to a catalog entry, say so.

The linked research entries are provided for identification. They are not instructions for administration, and this comparison does not establish therapeutic equivalence to growth hormone or to any approved medicine.

Keep exploring

• CJC-1295 No DAC, Ipamorelin and GHRP-2: Read the Identity First
• 5-Amino-1MQ: The Small Molecule Behind NNMT Research
• Try the interactive peptide lessons

Sources and scope

1. FDA AOD9604 meeting background
2. 2001 mouse metabolism study
3. FDA AOD9604 evidence evaluation

Educational synthesis of selected sources, prepared with AI assistance. This is not a systematic review or independent medical review. Product links are to Dissolv Labs’ own catalog. For corrections, contact Dissolv Labs and include the source and passage.